Abstract
Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Current Pharmaceutical Design
Title: Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Daniela M. Arduino, A. Raquel Esteves, Diana F.F. Silva, Diogo Martins-Branco, Daniel Santos, Diana F. Gomes Pimentel and Sandra M. Cardoso
Affiliation:
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Abstract: Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Export Options
About this article
Cite this article as:
M. Arduino Daniela, Raquel Esteves A., F.F. Silva Diana, Martins-Branco Diogo, Santos Daniel, F. Gomes Pimentel Diana and M. Cardoso Sandra, Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072481
DOI https://dx.doi.org/10.2174/138161211798072481 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Depression and Treatment with Effective Herbs
Current Pharmaceutical Design CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Coagulation Disorders in Acute Lung Injury
Current Respiratory Medicine Reviews Biochemical and Docking Analysis of Substrate Interactions with Polyisoprenylated Methylated Protein Methyl Esterase
Current Cancer Drug Targets 3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors
Current Neuropharmacology Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases
Current Drug Metabolism Possible Use of Autologous Stem Cell Therapies for Alzheimers Disease
Current Alzheimer Research Protein Quality Control in Alzheimers Disease: A Fatal Saviour
Current Drug Targets - CNS & Neurological Disorders Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry Vaccination in Pregnancy
Current Pharmaceutical Biotechnology The Amyloid β-Protein Precursor and Alzheimers Disease. Therapeutic Approaches
Current Medicinal Chemistry - Central Nervous System Agents Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry We are not Alone in Our Body: Insights into the Involvement of Microbiota in the Etiopathogenesis and Pharmacology of Mental Illness
Current Drug Metabolism Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis
Current Neurovascular Research The Interactions Between Alzheimer’s Disease and Major Depression: Role of Ca<sup>2+</sup> Channel Blockers and Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews